ORGANIZATION
New Special Rule for “Indication Change” Re-Pricing Significantly Lacks Predictability: FPMAJ
A new special rule introduced this April to expand the coverage of “indication change re-pricing” significantly lacks predictability and should be carefully applied given that it is implemented merely based on projections, the Federation of Pharmaceutical Manufacturers’ Associations of Japan…
To read the full story
Related Article
ORGANIZATION
- JPMA, EFPIA Follow PhRMA in Decrying CEA Price Cut Expansion
November 19, 2026
- PhRMA Slams CEA Expansion, Warns It Undermines Japan Growth Strategy
November 17, 2026
- UCB Japan President Kikuchi to Take Helm of EFPIA Japan
November 13, 2026
- Japan Pharmacy Group Renews Call to Scrap Off-Year Drug Price Revisions
November 13, 2026
- JPMA to Draw Up 2027 Strategic Plan Based on Industry Vision
November 13, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





